Search
Displaying 31–40 of 556 for “Retinitis pigmentosa”
-
Recording Available: Insights Forum | Friday, December 12, 2025
Foundation NewsThe Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the blinding diseases community. The call took place on December 12, 2025.
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
Research NewsThe Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
Research NewsThe clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
-
Fighting RP on the Foundation’s Frontline
Beacon StoriesMichelle Glaze, the Foundation’s associate director of professional outreach, shared her personal story of being diagnosed with retinitis pigmentosa (RP) in the film ‘Decoding disease.‘ In her own words, Michelle also describes her journey with genetic testing and the Foundation Fighting Blindness’ impact on her life.
-
Information for affected individuals and their families about the role of genetic counseling.
-
Story Update: Seeing Through Your Disability
Beacon StoriesLance Johnson shares life with retinitis pigmentosa (RP) as a creator, father, and Foundation Fighting Blindness ambassador—advocating for awareness and advancing treatments and cures.
-
RD Fund Invests in Beacon Therapeutics to Advance XLRP Gene Therapy
Research NewsThe venture philanthropy arm of the Foundation partnered with other investors to support the development of a gene therapy trial for X-linked retinitis pigmentosa (XLRP).
-
Foundation Fighting Blindness Provides Public Access to Data From its RUSH2A Natural History Study
Foundation NewsRUSH2A has captured extensive data over four years from patients with USH2A mutations causing non-syndromic retinitis pigmentosa and Usher syndrome type 2A.
.png)
